Ionis Pharmaceuticals (IONS) Invested Capital (2009 - 2026)

Ionis Pharmaceuticals' Invested Capital history runs 17 years deep, the most recent figure standing at $432.5 million for Q1 2026.

• On a quarterly basis, Invested Capital changed N/A year-over-year to $432.5 million in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 2291.16% increase from a year earlier, with the FY2025 full-year figure at $431.9 million, changed N/A from the prior year.
• Invested Capital was little changed at $432.5 million in Q1 2026 per IONS's latest filing, from $431.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $630.9 million in Q3 2025 and bottomed at $4.2 million in Q1 2022.
• The 5-year median for Invested Capital is $44.4 million (2024), against an average of $210.6 million.
• Across the five-year window, Invested Capital tumbled 93.2% in 2022 and jumped 1318.83% in 2025, its largest moves.
• Year by year, Invested Capital stood at $5.0 million in 2022, then soared by 791.99% to $44.3 million in 2023, then grew by 0.3% to $44.5 million in 2024, then jumped by 871.39% to $431.9 million in 2025, then increased by 0.13% to $432.5 million in 2026.
• Per Business Quant, the three latest IONS Invested Capital figures stand at $432.5 million (Q1 2026), $431.9 million (Q4 2025), and $630.9 million (Q3 2025).